^
Association details:
| Biomarker: | MET overexpression |
|---|---|
| Cancer: | Melanoma |
| Drug: | Zelboraf (vemurafenib) (BRAF inhibitor, BRAF V600E inhibitor) |
| Direction: | Resistant |
Evidence:
Source:
Title:
Non-genomic and Immune Evolution of Melanoma Acquiring MAPKi Resistance
Excerpt:
We identified in the tumor cell compartment supra-physiologic c-MET up-expression, infra-physiologic LEF1 down-expression and YAP1 signature enrichment as drivers of acquired resistance.
DOI:
10.1016/j.cell.2015.07.061
